Autopsy report · NCT05464836

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

“The sponsor requested termination due to internal reprioritization of resources.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 9 months before it started.
• Ran for about 1 year 4 months before it stopped.
• 2 participants enrolled.
• Results were posted on the registry 1 year 3 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

M.D. Anderson Cancer Center

Sponsor type

University, hospital or other

Conditions

Leukemia, Lymphoblastic; Leukemia

Interventions

CB-103; Venetoclax

Participants

2

Sites

1

Countries

United States

Trials that died the same way

• Pomalidomide With Melphalan and Dexamethasone for Untreated Systemic AL Amyloidosis
  “Sponsor requested termination” (83% match in meaning)
• A Clinical Study of IMP4297 Capsule (JS109) Combined With Irinotecan in the Treatment of Advanced Malignant Solid Tumors
  “The sponsor voluntarily requested termination” (81% match in meaning)
• Evaluation of Cranioplasty Using Native Bone Autograft Versus Synthetic Bone Allograft
  “Sponsor termination” (77% match in meaning)
• Assessing the Clinical Benefit of Molecular Profiling in Patients With Solid Tumors
  “Sponsor's discretion to termination due to business decision.” (76% match in meaning)
• Pilot Study Evaluating the Use of Nasal Carbon Dioxide for the Treatment of Cluster Headache
  “Terminated at the request of the financial sponsor.” (76% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.